PE20020216A1 - PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS - Google Patents

PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS

Info

Publication number
PE20020216A1
PE20020216A1 PE2001000584A PE2001000584A PE20020216A1 PE 20020216 A1 PE20020216 A1 PE 20020216A1 PE 2001000584 A PE2001000584 A PE 2001000584A PE 2001000584 A PE2001000584 A PE 2001000584A PE 20020216 A1 PE20020216 A1 PE 20020216A1
Authority
PE
Peru
Prior art keywords
alkyl
refers
nucleoside
aryl
substituted
Prior art date
Application number
PE2001000584A
Other languages
English (en)
Inventor
Martin L Bryant
Jean-Louis Imbach
Gilles Gosselin
Original Assignee
Idenix Cayman Ltd
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd, Centre Nat Rech Scient filed Critical Idenix Cayman Ltd
Publication of PE20020216A1 publication Critical patent/PE20020216A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A PRODROGAS 3' DE 2' DESOXI-ß-L-NUCLEOSIDOS DONDE EL TERMINO 2'- DESOXI SE REFIERE A UN NUCLEOSIDO QUE NO TIENE SUSTITUYENTES EN POSICION 2' Y EL TERMINO PRODROGA 3' SE REFIERE A UN DESOXI-ß-L-NUCLEOSIDO QUE TIENE UNA PORCION SEPARABLE EN LA POSICION 3' INCLUYENDO ACILO Y UN L-AMINOACIDO. SE REFIERE A UN ß-L NUCLEOSIDO 3'-O-SUSTITUIDO DE FORMULA I DONDE R1 ES H, ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, ENTRE OTROS; R2 ES ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, CO-ARILOXIALQUILO, ENTRE OTROS; X ES O, S, SO2, CH2. EL COMPUESTO ß-L NUCLEOSIDO 3'-O-SUSTITUIDO ES UNA ß-L-2'-DESOXIPURINA DE FORMULA II DONDE R1 ES H, ALQUILO, CO-ALQUILO, CO-ARILO, CO-ALCOXIALQUILO, ENTRE OTROS; R2 ES ALQUILO, CO-ALQUILO, CO-ARILO, RESIDUO AMINOACIDO, MONO, DI, O TRIFOSFATO; Y ES OR3, NR3R4, SR3; X1 Y X2 SON H, ALQUILO, CO-ALQUILO, ENTRE OTROS; R3-R6 SON H, ALQUILO, DIALQUILAMINOALQUILENO DE PREFERENCIA DIMETILAMINOMETILENO, CO-ALQUILO ENTRE OTROS.I ADEMAS A COMPUESTOS DE B-L NUCLEOSIDO 3'-O-SUSTITUIDO TAL COMO B-L-2'-DESOXIPURINA, ß-L-2'-DESOXIADENOSINA, B-L-2'-DESO-GUANIDINA, B-L-2'-DESOXIINOSINA, B-L-2'-DESOXIPIRIMIDINA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE UNA INFECCION POR VIRUS DE HEPATITIS B
PE2001000584A 2000-06-15 2001-06-15 PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS PE20020216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21210000P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020216A1 true PE20020216A1 (es) 2002-04-16

Family

ID=22789563

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000584A PE20020216A1 (es) 2000-06-15 2001-06-15 PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS

Country Status (27)

Country Link
EP (1) EP1296995B1 (es)
JP (1) JP4639032B2 (es)
KR (2) KR20070048277A (es)
CN (3) CN1900104A (es)
AP (1) AP1771A (es)
AR (1) AR035711A1 (es)
AT (1) ATE411332T1 (es)
AU (2) AU6692701A (es)
BR (1) BR0111732A (es)
CA (1) CA2413163C (es)
CZ (1) CZ2003122A3 (es)
DE (1) DE60136181D1 (es)
EA (1) EA005774B1 (es)
ES (1) ES2317912T3 (es)
IL (3) IL153379A0 (es)
MA (1) MA27126A1 (es)
MX (1) MXPA02012443A (es)
MY (1) MY141594A (es)
NO (1) NO20026001L (es)
NZ (2) NZ535246A (es)
OA (1) OA12384A (es)
PE (1) PE20020216A1 (es)
PL (1) PL360404A1 (es)
UY (1) UY26779A1 (es)
WO (1) WO2001096353A2 (es)
YU (1) YU94802A (es)
ZA (2) ZA200300168B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136620D1 (de) 2000-04-13 2009-01-02 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374792A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PT1572095E (pt) 2002-09-13 2015-10-13 Novartis Ag Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
BRPI0408561A (pt) 2003-03-20 2006-03-21 Microbiol Quimica Farmaceutica métodos para manufatura de 2'-desoxi-59-l-nucleosìeos
WO2004096149A2 (en) * 2003-04-28 2004-11-11 Idenix (Cayman) Limited Industrially scalable nucleoside synthesis
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US20050059632A1 (en) 2003-06-30 2005-03-17 Richard Storer Synthesis of beta-L-2'-deoxy nucleosides
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP2008546708A (ja) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Hcvにおけるサングリフェリンの使用
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
CN102264917B (zh) 2008-06-11 2015-06-10 激光基因公司 核苷酸和核苷以及将其用于dna测序的方法
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CN104024269B (zh) 2011-09-13 2017-05-24 激光基因公司 5‑甲氧基,3’‑oh未阻断,可快速光切割的终止核苷酸以及用于核酸测序的方法
CN104244945B (zh) 2011-09-16 2016-08-31 吉利德制药有限责任公司 用于治疗hcv的方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
DK2950786T3 (da) 2013-01-31 2020-02-17 Gilead Pharmasset Llc Kombinationsformulering af to antivirale forbindelser
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
MX2020010667A (es) * 2018-04-12 2021-01-08 Modis Therapeutics Inc Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
SE9603178L (sv) * 1996-08-30 1997-09-22 Scania Cv Ab Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul
ES2579903T3 (es) * 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B

Also Published As

Publication number Publication date
MY141594A (en) 2010-05-14
IL178864A0 (en) 2007-03-08
UY26779A1 (es) 2001-12-28
ES2317912T3 (es) 2009-05-01
ZA200404306B (en) 2005-06-15
AP2003002713A0 (en) 2003-03-31
CA2413163A1 (en) 2001-12-20
IL153379A0 (en) 2003-07-06
WO2001096353A3 (en) 2002-04-18
AU6692701A (en) 2001-12-24
EA200300023A1 (ru) 2003-08-28
EA005774B1 (ru) 2005-06-30
AR035711A1 (es) 2004-07-07
KR20030032967A (ko) 2003-04-26
MA27126A1 (fr) 2005-01-03
CN1900104A (zh) 2007-01-24
CA2413163C (en) 2008-11-18
DE60136181D1 (de) 2008-11-27
CN1452627A (zh) 2003-10-29
NZ535246A (en) 2006-06-30
KR20070048277A (ko) 2007-05-08
YU94802A (sh) 2006-03-03
ZA200300168B (en) 2004-07-07
WO2001096353A2 (en) 2001-12-20
NO20026001D0 (no) 2002-12-13
BR0111732A (pt) 2003-06-24
ATE411332T1 (de) 2008-10-15
NZ523632A (en) 2005-03-24
NO20026001L (no) 2003-02-12
AU2001266927B2 (en) 2006-12-14
JP2004533403A (ja) 2004-11-04
JP4639032B2 (ja) 2011-02-23
EP1296995A2 (en) 2003-04-02
CN101012259A (zh) 2007-08-08
CZ2003122A3 (cs) 2003-06-18
IL153379A (en) 2007-02-11
AP1771A (en) 2007-08-23
EP1296995B1 (en) 2008-10-15
OA12384A (en) 2006-04-17
CN1295242C (zh) 2007-01-17
PL360404A1 (en) 2004-09-06
MXPA02012443A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
PE20020216A1 (es) PRODROGAS 3' DE 2' -DESOXI-ß-L-NUCLEOSIDOS
RU2478104C2 (ru) Нуклеозидфосфорамидаты в качестве противовирусных агентов
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
RU2327701C2 (ru) Нуклеозидные производные и фармацевтическая композиция, обладающая антивирусной активностью в отношении hcv
DE122007000062I1 (de) Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus
RU2009123104A (ru) Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с
AR043298A1 (es) Prodrogas 2' y 3' de nucleosidos para tratar infecciones de flaviviridae, composiciones farmaceuticas, sus usos en la manufactura de medicamentos y metodos de tratamiento
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
PE20001072A1 (es) Antivirales derivados de purinas
AR035336A1 (es) Metodo para el tratamiento o profilaxis de una infeccion por el virus de hepatitis c
BR0110023A (pt) Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
EA200300819A1 (ru) Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
ES2125251T3 (es) Inhibidores de la proteasa del vih.
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
AR031520A1 (es) Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
HUP0101715A2 (hu) Eljárások és készítmények reumatoid artritisz kezelésére
AR021577A1 (es) Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos
AR018707A1 (es) Composicion farmaceutica para tratar infecciones virales
AR035301A1 (es) Drogas antivirales
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
UY27030A1 (es) Inhibidores del virus de hepatitis c
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed